507294876 05/20/2022

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7341801

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
SINGH BIOTECHNOLOGY, LLC	05/19/2022

## **RECEIVING PARTY DATA**

Name:	SINGH MOLECULAR MEDICINE, LLC	
Street Address:	1547 FOX GRAPE LOOP	
City:	LUTZ	
State/Country:	FLORIDA	
Postal Code:	33558	

# **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	16195542

## **CORRESPONDENCE DATA**

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 6193986772

Email: ipdocket@matrix.law

Correspondent Name: LAURA M. KING PH.D. J.D. Address Line 1: MATRIX LAW GROUP, LLP

Address Line 2:5205 AVENIDA ENCINAS, SUITE AAddress Line 4:CARLSBAD, CALIFORNIA 92008

ATTORNEY DOCKET NUMBER:	51293-15
NAME OF SUBMITTER:	LAURA M. KING, PH.D., J.D.
SIGNATURE:	/Laura M. King/
DATE SIGNED:	05/20/2022

**Total Attachments: 1** 

source=20220519 eExecuted Assignment for 51293-15#page1.tif

PATENT REEL: 059972 FRAME: 0257

507294876

### ASSIGNMENT OF RIGHTS

WHEREAS, Singh Biotechnology, LLC, a Florida limited liability company, ("the Assignee"), having a post office address of 14153 Yosemite Drive, Suite 101, Hudson, Florida 34667, United States has or may have rights in certain new and useful improvements disclosed in United States Patent Application titled "Single Domain Antibodies Directed Against Intracellular Antigens," having Serial No. 16/195,542 filed on November 19, 2018, (the "Patent Application"); and

WHEREAS, Singh Molecular Medicine, LLC, a Florida limited liability company (hereinafter, together with any successors, legal representatives or assigns thereof, called "ASSIGNEE"), having an address of 1547 Fox Grape Loop, Lutz, Florida 33558, United States, wants to acquire the entire right, title, and interest that Assignor has or may have in the Patents and Patent Applications;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the Assignor, by these presents does sell, assign and transfer to the Assignee the Rights in and to the Patents and Patent Applications and to all divisions, substitutions, continuations and continuations-in-part thereof, and all United States Letters Patents which may be granted thereon and all reissues and extensions thereof, and all priority rights under the International Convention for the Protection of Industrial Property for every member country, and all applications for patents (including related rights such as utility-model registrations, inventor's certificates, and the like) heretofore or hereafter filed for said improvements in any foreign countries, and all patents (including all extensions, renewals and reissues thereof) granted for said improvements in any foreign countries; and I hereby authorize and request the United States Commissioner of Patents and Trademarks, and any officials of foreign countries whose duty it is to issue patents on applications as aforesaid, to issue all patents for said improvements to Assignee in accordance with the terms of this assignment; and to all reissues thereof to the full end of the term for which the Patents and Patent Applications are granted; and

AND the Assignee covenants and agrees that it will cooperate in any legal proceeding, cause to be executed all lawful papers, cause to be executed all reissue applications, cause to be made all rightful oaths and generally do everything possible to aid Assignee to enforce the Patents and Patent Applications in the United States.

IN TESTIMONY WHEREOF, I, the undersigned, am empowered to act on behalf of the ASSIGNOR, and I hereunto set my hand this 19 day of May , 2022.

Sunanda Singh, M.D., Ph.D. Officer Name: Sunanda Singh, M.D., Ph.D.

Officer Title: Manager and Chief Executive Officer

Singh Biotechnology, LLC

Assignee hereby accepts this Assignment:

Sunanda Singh, M.D., Ph.D. Date: May 19, 2022

Officer Name: Sunand Singh, M.D., Ph.D.
Officer Title: Manager and Chief Executive Officer

Singh Molecular Medicine, LLC

PATENT REEL: 059972 FRAME: 0258

**RECORDED: 05/20/2022**